Safety and Effectiveness of Rasburicase in the Control of Hyperuricemia in Pediatric Patients with Non-Hodgkin’s Lymphoma and Acute Leukemia: An Open-Label, Single-Arm, Multi-center, Interventional Study

• Published in: Drugs in R&D Vol. 23; no. 2; pp. 129 - 140
• Main Authors: Wang, Tianyou, Zhu, Xiaofan, Chen, Yumei, Shen, Shuhong, Tang, Yongmin, Zhang, Jingying, He, Yingyi, Zhang, Hui, Gao, Ju, Fang, Jianpei, Liu, Rong, Wu, Xiaoyan, Sun, Jinchuan, Zhang, Minlu
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.06.2023; Springer Nature B.V; Adis, Springer Healthcare
• Subjects: Birth control; Blood; Chemotherapy; Child; Child, Preschool; China; Clinical trials; Dehydrogenases; Drug dosages; Enzymes; FDA approval; Female; Hematology; Humans; Hydration; Hyperuricemia - complications; Hyperuricemia - drug therapy; Internal Medicine; Leukemia; Leukemia - complications; Lymphoma; Lymphoma, Non-Hodgkin - complications; Male; Medicine; Medicine & Public Health; Oncology; Original; Original Research Article; Patients; Pediatrics; Pharmacology/Toxicology; Pharmacotherapy; Plasma; Prevention; Recombinant Proteins - adverse effects; Recombinant Proteins - therapeutic use; Uric Acid; Vital signs; China

Introduction Despite rasburicase's proven efficiency in Caucasians, Japanese, and Koreans, studies evaluating the safety and effectiveness of rasburicase in Chinese pediatric patients with non-Hodgkin’s lymphoma (NHL) and acute leukemia (AL) in particular are lacking. Objective The aim was to e...